Alexander Cox

54 posts

Alexander Cox banner
Alexander Cox

Alexander Cox

@AlexanderCoxMD

Urologist | FEBU @UniklinikBonn - University Hospital Bonn, Germany

Bonn, Deutschland Katılım Temmuz 2022
133 Takip Edilen80 Takipçiler
Alexander Cox retweetledi
Dr_KevinZorn
Dr_KevinZorn@Dr_KevinZorn·
Starting soon #EAU25 #BPH GAME CHANGER session - late breaking release of WATER3 RCT HOLEP vs @myaquablation @PROCEPTRobotics - 1015-1030am Green area. Is Aquablation as effective, efficient and safe for prostates 80-180cc? Come find out!
Dr_KevinZorn tweet mediaDr_KevinZorn tweet mediaDr_KevinZorn tweet mediaDr_KevinZorn tweet media
English
1
1
7
561
Alexander Cox retweetledi
Dr. Bishoy M. Faltas
Dr. Bishoy M. Faltas@FaltasLab·
Excited to be part of this exciting review @NatRevNeurol "Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer" with @niklas_kluemper @AlexanderCoxMD @GottfridSjodahl @roghmann @ViktorGruenwald @HolzelMichael @Markuseckstein3
Niklas Klümper@niklas_kluemper

Thrilled to share our review published today in Nature Reviews Urology! @NatRevUrol: rdcu.be/dYuu1 "Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer" Thanks to the amazing team of collaborators @AlexanderCoxMD @GottfridSjodahl @roghmann @ViktorGruenwald @FaltasLab @HolzelMichael @Markuseckstein3 We are exploring how real-time biopsies of metastases could capture the heterogeneity of met. UC, which could provide a clearer path to effective, targeted treatments for mUC! #PrecisionOncology #UrothelialCancer #CancerResearch @OncoAlert #OncoAlertAF @weoncologists @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @matteolambe @Icro_Meattini @NarjustFlorezMD @double_whammied @JaniceTNBCmets @ARosen380 @kevinpunie @scserendipity1 @CathyEngMD @PGrivasMDPhD @tompowles1 @Uromigos @DrChoueiri @urotoday @DrYukselUrun @shilpaonc @PTarantinoMD

English
1
9
27
1.8K
Alexander Cox retweetledi
Niklas Klümper
Niklas Klümper@niklas_kluemper·
Thrilled to share our review published today in Nature Reviews Urology! @NatRevUrol: rdcu.be/dYuu1 "Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer" Thanks to the amazing team of collaborators @AlexanderCoxMD @GottfridSjodahl @roghmann @ViktorGruenwald @FaltasLab @HolzelMichael @Markuseckstein3 We are exploring how real-time biopsies of metastases could capture the heterogeneity of met. UC, which could provide a clearer path to effective, targeted treatments for mUC! #PrecisionOncology #UrothelialCancer #CancerResearch @OncoAlert #OncoAlertAF @weoncologists @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @matteolambe @Icro_Meattini @NarjustFlorezMD @double_whammied @JaniceTNBCmets @ARosen380 @kevinpunie @scserendipity1 @CathyEngMD @PGrivasMDPhD @tompowles1 @Uromigos @DrChoueiri @urotoday @DrYukselUrun @shilpaonc @PTarantinoMD
Niklas Klümper tweet media
English
0
15
41
4.7K
Alexander Cox retweetledi
Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri·
Interesting work from @niklas_kluemper et al —Na levels may module ICB response. Still so much unknown in this area. Congrats for the elegant work Niklas!
Niklas Klümper@niklas_kluemper

We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting observation: ejcancer.com/article/S0959-… ➡️High serum sodium predicts ICB response in mRCCl and mUC! ➡️Baseline sodium could serve as a valuable and cost-effective predictive biomarker for ICB (it outperforms PD-L1!) ➡️Sodium exhibits a linear correlation with survival in immunotherapy-treated patients ➡️This hypothesis-generating data suggests that more sodium might fuel an antitumor immune response! ➡️Consistent with this, there is growing evidence of a direct immune-modulating effect of sodium; e.g. High salt diet (HSD) inhibits tumor growth in mice by enhancing anti-tumor immunity ➡️ Maybe HSD could have a synergistic effect with ICB? Further research is needed! Thanks to all collaborators @AlexanderCoxMD @Markuseckstein3 @KuppeChristoph @HolzelMichael @IEO_HolzelLab @JohannesStein9 @saal_jonas @ImmunoSens and to the support from @BMBF_Bund @ @Krebshilfe_Bonn @EORTC @OncologyAdvance @myESMO @Uroweb @UrowebESU @DrChoueiri @ASCO @JCOPO_ASCO @OncoAlert @urotoday @PTarantinoMD @Erman_Akkus @drenriquegrande @PGrivasMDPhD @amerseburger @DrYukselUrun @tompowles1 @Uromigos @montypal @neerajaiims @shilpaonc @sonpavde #Oncology #Cancer #Immunotherapy

English
1
11
22
6.2K
Alexander Cox retweetledi
Niklas Klümper
Niklas Klümper@niklas_kluemper·
We are happy to share our current manuscript: In an exploratory post-hoc analysis of IMmotion151 (mRCC, atezo + beva) and IMvigor211 (mUC, atezo), in which we correlated baseline electrolyte concentration with ICB response and outcome in an unbiased manner, we made an interesting observation: ejcancer.com/article/S0959-… ➡️High serum sodium predicts ICB response in mRCCl and mUC! ➡️Baseline sodium could serve as a valuable and cost-effective predictive biomarker for ICB (it outperforms PD-L1!) ➡️Sodium exhibits a linear correlation with survival in immunotherapy-treated patients ➡️This hypothesis-generating data suggests that more sodium might fuel an antitumor immune response! ➡️Consistent with this, there is growing evidence of a direct immune-modulating effect of sodium; e.g. High salt diet (HSD) inhibits tumor growth in mice by enhancing anti-tumor immunity ➡️ Maybe HSD could have a synergistic effect with ICB? Further research is needed! Thanks to all collaborators @AlexanderCoxMD @Markuseckstein3 @KuppeChristoph @HolzelMichael @IEO_HolzelLab @JohannesStein9 @saal_jonas @ImmunoSens and to the support from @BMBF_Bund @ @Krebshilfe_Bonn @EORTC @OncologyAdvance @myESMO @Uroweb @UrowebESU @DrChoueiri @ASCO @JCOPO_ASCO @OncoAlert @urotoday @PTarantinoMD @Erman_Akkus @drenriquegrande @PGrivasMDPhD @amerseburger @DrYukselUrun @tompowles1 @Uromigos @montypal @neerajaiims @shilpaonc @sonpavde #Oncology #Cancer #Immunotherapy
Niklas Klümper tweet mediaNiklas Klümper tweet media
English
3
17
45
13.4K
Alexander Cox retweetledi
Erman Akkus
Erman Akkus@Erman_Akkus·
💉🩸High serum sodium predicts response to IO in mUC and mRCC @EORTC @OncologyAdvance ➡️Posthoc analyses of IMvigor211 (mUC, atezolizumab) and IMmotion151 (mRCC, atezolizumab+bevacizumab) trials ✅Baseline serum sodium levels of >140mmol/L : higher objective response⬆️ ✅Serum sodium outperformed tumor PD-L1 expression 👉ejcancer.com/article/S0959-… @myESMO @Uroweb @UrowebESU @DrChoueiri @DrYukselUrun @yekeduz_emre @NazliDizman @Uromigos @OncoAlert #Oncology #Cancer #immutheraphy #MedX
Erman Akkus tweet media
English
2
24
66
6.5K
Alexander Cox retweetledi
Tom Powles
Tom Powles@tompowles1·
New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24
Tom Powles tweet mediaTom Powles tweet mediaTom Powles tweet mediaTom Powles tweet media
English
1
79
199
16.9K
Alexander Cox retweetledi
Niklas Klümper
Niklas Klümper@niklas_kluemper·
What a start at #EAU24 - OS Update of CheckMate274 Adjuvant Nivolumab demonstrates OS benefit for high-risk MIBC, especially in PD-L1+ population! (HR 0.56) @MattGalsky But: Why did adjuvant Nivo perform better than Pembro (AMBASSADOR did not demonstrate OS benefit @ASCO #GU24)! We need biomarkers! ctDNA guidance can help to identify the patients at highest-risk of recurrence with need for adjuvant IO @tompowles1 But also biomarkers to predict IO response are needed! @Markuseckstein3 Great discussion by Joost Boormans! @ErasmusMC We also need to consider that SOC 1L mUC therapy has changed -> EV/PEM (EV-302) with mOS > 30month. Maybe even ctDNA+ patients would benefit more from surveillance and EV/P after disease recurrence? @JoshMeeks @PGrivasMDPhD @urotoday @ViktorGruenwald @Uromigos @Uroweb
Niklas Klümper tweet mediaNiklas Klümper tweet mediaNiklas Klümper tweet media
English
2
21
58
13.6K
Alexander Cox retweetledi
Niklas Klümper
Niklas Klümper@niklas_kluemper·
Nectin-4—drug conjugates (in metastatic urothelial carcinomas): The right drug for everyone? Happy to talk about current evidence to use Nectin-4 status to predict Enfortumab vedotin response in met. UC at #EAU24 in Paris @Uroweb ! Very interesting Session on saturday about „Tumour and patient biology for optimised treatment“ 🎯 @LDyrskjot @JLinxweiler @Markuseckstein3 @ViktorGruenwald @imedverse @drenriquegrande @DrYukselUrun @amerseburger @urotoday
Niklas Klümper tweet media
English
2
20
60
6.6K
Alexander Cox retweetledi
Niklas Klümper
Niklas Klümper@niklas_kluemper·
Happy to share or words of wisdom commentary @EUplatinum about ADC development for Penile squamous cell carcinoma (PSCC)! @JLinxweiler @Markuseckstein3 @Uroweb ➡️Targeting common antigens like TROP2 or NECTIN-4 is a promising avenue to develop tumor-agnostic ADC treatment in rare cancers like PSCC, which are often overlooked in clinical trials🎯 ➡️Case report provides first evidence of EV response in a heavily pretreated patient with NECTIN4+ PSCC ➡️Phase II trial of EV in PSCC recently started recruiting patients (NCT06104618) @ViktorGruenwald @SpiessPhilippe @amerseburger @drenriquegrande @PGrivasMDPhD @shilpaonc @PTarantinoMD @urotoday @OncoAlert @imedverse authors.elsevier.com/a/1ilN-14kplyx…
English
1
7
18
3.8K
Alexander Cox retweetledi
Dr. Bishoy M. Faltas
Dr. Bishoy M. Faltas@FaltasLab·
Excited to share our new paper just published @NatureComms @WCMGUcancer @WeillCornell nature.com/articles/s4146… Great collaboration between my lab with @ElementoLab @WCMEnglanderIPM and J.M. Mosquera @WCMCPathology 🔬 Full tweetorial below with more updates to come. Stay tuned!
Dr. Bishoy M. Faltas tweet mediaDr. Bishoy M. Faltas tweet media
Dr. Bishoy M. Faltas@FaltasLab

Excited to share our new @biorxivpreprint: The evolution of genomic, transcriptomic, and immune features of metastatic upper tract urothelial carcinoma biorxiv.org/content/10.110…. A #Teamscience project spearheaded by K. Ohara and co-led by @FaltasLab and J.M. Mosquera

English
17
39
201
30.5K
Alexander Cox retweetledi
Niklas Klümper
Niklas Klümper@niklas_kluemper·
Great to see EV-302 data finally published @NEJM! Big step for patients with metastatic UC with doubling in OS! ➡️Open questions are which patients in particular benefit from EV/P and which patients only achieve short-term response or have primary EV/P resistance? ➡️Prediction of EV/P resistance is key to develop better treatment options for this population NECTIN4 status 🔍 High membranous NECTIN4 expression or NECTIN4 amplification are promising predictive biomarkers! More biomarker work needed to better understand EV/P resistance! @Markuseckstein3 @JCO_ASCO @Uroweb @urotoday @imedverse @ViktorGruenwald @amerseburger @drenriquegrande @shilpaonc @FaltasLab @tompowles1 @Uromigos
NEJM@NEJM

In a trial comparing enfortumab vedotin and a PD-1 inhibitor with chemotherapy in patients with untreated advanced or metastatic urothelial cancer, progression-free and overall survival nearly doubled with the experimental treatment. Full trial results: nej.md/49ViJEe

English
3
11
25
8K
Alexander Cox retweetledi
Markus Eckstein
Markus Eckstein@Markuseckstein3·
Sacituzumab + Pembro is efficacious in metastic urothelial cancer following progress on platinum based chemotherapy !! Very interesting study by @PGrivasMDPhD and @y_loriot and team that unfortunately comes late. Is there still a place for this regimen after EV302 results ? But underlines the performance of SG! ➡️options in the ADC 🏄‍♂️ space is clnstsntly expanding ! ➡️ and TROP 2 is highly expressed in UC! @DrYukselUrun @shilpaonc @niklas_kluemper @urotoday @OncoAlert @ViktorGruenwald ascopubs.org/doi/10.1200/JC…
English
1
16
28
11.8K
Alexander Cox retweetledi
Niklas Klümper
Niklas Klümper@niklas_kluemper·
Prediction of therapy response based on RECIST criteria only has limitations for the immunotherapy era! Longitudinal assessment of simple inflammatory 🔥blood biomarkers (CRP + albumin integrated into modified Glasgow Prognostic Score/ mGPS) provides complementary information to radiological staging for ICB-treated NSCLC, especially for heterogenous subgroup with stable disease! 🎯 We validated this simple new concept to improve therapy monitoring for ICB-treated mRCC @JAMAOnc jamanetwork.com/journals/jamao… mUC @EurUrolOncol sciencedirect.com/science/articl… and now NSCLC! @myESMO doi.org/10.1016/j.lung… @Markuseckstein3 @urotoday @OncoAlert @OncBrothers @imedverse
Niklas Klümper@niklas_kluemper

Happy to share our work: Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma @JAMAOnc. See our tweetorial and the terrific editorial by @ggebraelmd @GliceidaGalarza @neerajaiims @urotoday 1/7

English
0
11
17
6.3K
Alexander Cox retweetledi
Markus Eckstein
Markus Eckstein@Markuseckstein3·
Long Term results from PROFOUND out. Clearly showing the tremendous (🧪) predictive potential of deleterious BRCA alterations for PARP inhibitor Olaparib in metastatic castration resistant #prostatecancer!! Although certainly not powered for that: ‼️ germline BRCA patients tend to have greater benefits ➡️ known for ovarian cancer! 🔬 these results should be an eye opener for everyone who believe in all comer efficacy of PARPi ➡️ biologically and clinically it makes no sense to apply targeted therapies without having a target 🎯 we need to test it - either in 🧪 or tissue. @ASCO @Uroweb @Uromigos @imedverse @urotoday @OncoAlert @niklas_kluemper @VPrasadMDMPH ascopubs.org/doi/10.1200/JC…
English
0
9
19
3.5K
Alexander Cox retweetledi
Markus Eckstein
Markus Eckstein@Markuseckstein3·
Our latest paper ist out in @Histo_Journal ! We comprehensively studied the membranous protein expression of the two important #ADC targets TROP2 and NECTIN4 (surfaceome 🏄‍♂️). it is the first paper on protein expression in a large cohort of over 200 muscle-invasive and metastic carcinomas of the urinary bladder. 😊 ➡️read below! @OncoAlert @Uroweb @onkowissen @ASCO @JAMA_current @JAMANetwork @urotoday @niklas_kluemper @IEO_HolzelLab @HolzelMichael onlinelibrary.wiley.com/doi/10.1111/hi…
English
2
12
34
11.2K

Keşfet

@myaquablation @PROCEPTRobotics @BenjaminPradere @Markuseckstein3 @NatRevNeurol @niklas_kluemper @GottfridSjodahl @ViktorGruenwald